Connect with us

Health

Fidson, Nigeria’s largest pharmaceutical company, delivers N3.6 billion dividend to shareholders

info

Published

on

IMG 2947.JPG scaled.jpeg

MTN ADVERT

Shareholders of the largest pharmaceutical company in Nigeria, Fidson Healthcare Plc, approved a dividend of ₦1.50 per 50 kobo ordinary share, amounting to ₦3.6 billion, at the Company’s 27th Annual General Meeting held virtually on Thursday, 30 July.

The approval comes against the backdrop of a year in which the company achieved key milestones in its growth trajectory. It also coincides with the one-year anniversary of the smooth transition of leadership at both the Board and Management level — a transition shareholders acknowledged as a testament to Fidson’s strong corporate governance culture and succession planning. It also reflects shareholders’ confidence in the Company’s continued ability to deliver sustainable value despite a challenging operating environment.

The Founder and Chairman of Fidson, Fidelis Ayebae, in his address to shareholders, said 2025 marked a defining year in the history of the Company.

“We recorded revenue of ₦119.06 billion, becoming the first pharmaceutical company in Nigeria to surpass the ₦100 billion annual revenue milestone. This achievement reflects the dedication of our people, the confidence of our shareholders, and the effectiveness of our long-term growth strategy.”

Also recognising critical enablers of the business, Mr Ayebae expressed his profound gratitude to the Federal Government of Nigeria for improving the operating environment for local pharmaceutical manufacturers through strategic policies that have strengthened the ability of industry players like Fidson to meet the high demand for pharmaceutical products at affordable prices for Nigerians.

PT WHATSAPP CHANNEL
L-RMr. Ola Ijimakin; Commercial Director, Fidson; Mrs. Hannah Oyebanjo, Non-Executive Director; Mr. Imokha Ayebae; Finance Director; Dr. Fidelis Ayebae, Chairman; and Mr. Abiola Adebayo, Managing Director/CEO at the 27th Annual General Meeting of Fidson Healthcare Plc which held virtually on July 30, 2026.
L-R Mr. Ola Ijimakin; Commercial Director, Fidson; Mrs. Hannah Oyebanjo, Non-Executive Director; Mr. Imokha Ayebae; Finance Director; Dr. Fidelis Ayebae, Chairman; and Mr. Abiola Adebayo, Managing Director/CEO at the 27th Annual General Meeting of Fidson Healthcare Plc which held virtually on July 30, 2026.

Mr Ayebae added that, beyond financial performance, the Company continued to make strategic investments that will shape the future of healthcare manufacturing in Africa. He said:

“Our ongoing expansion projects have reached advanced stages and, upon completion, will position Fidson as the largest and most sophisticated pharmaceutical manufacturing company in Sub-Saharan Africa. We are confident that Fidson is well-positioned to deliver sustainable growth, deepen healthcare access, and continue to create superior value for our shareholders and all stakeholders.”

Responding to questions and comments from shareholders, the Managing Director/Chief Executive Officer, Biola Adebayo, reaffirmed the Company’s commitment to sustaining growth through innovation, manufacturing excellence, and strategic investments.

“Our focus remains clear—to deepen our manufacturing capabilities, widen our product portfolio, improve market penetration, and build a healthcare institution that delivers value to consumers, healthcare professionals, shareholders, and society at large. We will achieve this by leveraging emerging opportunities across Africa and continually strengthening our processes for sustainable growth.”

Mrs. Hannah Oyebanjo, Non-Executive Director; Mr. Imokha Ayebae; Finance Director; Mr. Abiola Adebayo, Managing Director/CEO; Dr. Fidelis Ayebae, Chairman; Mr Yomi Adebanjo, Company Secretary and Dr (Mrs) Amina Muhammed-Baloni Non-Executive Director at the 27th Annual General Meeting of Fidson Healthcare Plc which held virtually on July 30, 2026.
Mrs. Hannah Oyebanjo, Non-Executive Director; Mr. Imokha Ayebae; Finance Director; Mr. Abiola Adebayo, Managing Director/CEO; Dr. Fidelis Ayebae, Chairman; Mr Yomi Adebanjo, Company Secretary and Dr (Mrs) Amina Muhammed-Baloni Non-Executive Director at the 27th Annual General Meeting of Fidson Healthcare Plc which held virtually on July 30, 2026.

Shareholders who spoke during the meeting commended the Board and Management for maintaining the Company’s growth trajectory and a dividend policy that rewards investors while preserving adequate resources for future expansion. They also expressed confidence in the management’s ability to build on existing achievements and further strengthen Fidson’s position as the leading pharmaceutical manufacturing company in Nigeria.

In addition to approving the dividend, shareholders considered and approved the resolutions presented at the AGM, including the election and re-election of directors, authorisation to fix auditors’ remuneration, and the election of members of the Statutory Audit Committee, further reinforcing the Company’s commitment to transparency, accountability, and sound corporate governance.

The meeting also highlighted Fidson’s continued commitment to accessible shareholder engagement through the use of electronic annual reports, e-dividend platforms, and virtual AGM participation, enabling shareholders to participate more conveniently in the affairs of the Company.

As Fidson Healthcare Plc moves into a new phase of growth, the Company remains committed to its vision of adding value to lives through quality pharmaceutical products while delivering sustainable returns to shareholders and contributing meaningfully to the development of Africa’s healthcare ecosystem.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Ebola: WHO expresses hope as cases surpass 10,000, deaths near 5,000 in DRC

info

Published

on

Ebola.jpg

The World Health Organisation (WHO) has expressed hope that the Ebola outbreak in the Democratic Republic of the Congo (DRC) can be contained, despite confirmed cases of Bundibugyo virus disease surpassing 10,000.

The optimism comes as data released by the DRC’s Ministry of Public Health on Tuesday put confirmed cases at 10,060, with 4,887 deaths, according to a report by Al Jazeera.

The outbreak, declared on 15 May, is the largest and deadliest Ebola epidemic recorded in the DRC.

It is also the second-largest and second-deadliest Ebola outbreak globally, behind the 2014–2016 West African epidemic, which recorded about 28,600 cases and more than 11,000 deaths.

Reasons for hope

In a post on his official X account on Tuesday, Mohammed Janabi, the WHO Regional Director for Africa, said the rising figures reflected the toll the outbreak had taken on families and communities but noted that progress in recovery, research and response efforts offered reasons for hope.

Mr Janabi said more than 2,600 people had recovered, while new vaccine and treatment candidates were advancing through clinical trials.

PT WHATSAPP CHANNEL
Dangote Refinery AD

He added that laboratory testing, treatment capacity, infection prevention and control, community engagement and surveillance were being strengthened to help contain the outbreak.

“Our teams are on the ground, working side by side with the government and partners to stop transmission and save lives,” he said, calling for sustained commitment, community trust and solidarity, as well as safe access to affected communities.

Spread beyond the DRC

The rising figures come amid growing concerns about the spread of the virus beyond the DRC, with Kenya and Nigeria reporting infections linked to the wider outbreak.

PREMIUM TIMES reported last week that Kenya had recorded nine confirmed cases, including two deaths, after the virus was introduced by a traveller who arrived from the DRC through Uganda.

Nigeria also confirmed its first Ebola case in more than a decade on 20 October, after a woman who had travelled from Uganda tested positive in the Federal Capital Territory (FCT).

In a subsequent report, PREMIUM TIMES reported that the Africa Centres for Disease Control and Prevention (Africa CDC) was investigating a possible link between the Nigerian case and the infection recorded in Kenya.

Both patients travelled through Entebbe International Airport in Uganda on 3 October, prompting investigations into whether they had shared equipment or had other contact. However, health officials have stressed that a direct connection between the infections has not been established.

Nigeria’s health minister, Muhammad Pate, later said genomic sequencing showed that the viruses detected in Nigeria and Kenya differed by only one mutation. He cautioned, however, that the finding did not establish where the Nigerian patient contracted the virus.

Contact tracing challenges

According to the Al Jazeera report, about 80 per cent of new cases in the DRC are occurring outside the known chains of transmission being monitored by health authorities.

This means many infections are being detected among people whose exposure to previously confirmed cases has not been established, complicating efforts to identify contacts and interrupt further transmission.

The Africa CDC has said at least 95 per cent of cases must be linked to known contacts of infected people for an outbreak to be considered under control.

Vaccine research underway

The absence of an approved vaccine against the Bundibugyo strain remains another major challenge in the response.

PREMIUM TIMES reported on Friday that the World Health Organisation (WHO) had announced the commencement of the Tumaini clinical trial in Bunia, eastern DRC, to assess potential vaccines against the strain.

READ ALSO: Ebola: Nigeria has no active case after patient’s evacuation — WHO

The trial began with the vaccination of its first participants on 23 October and is expected to evaluate several vaccine candidates, including Ervebo, which is licensed against a different Ebola virus species, as well as experimental candidates being developed by Moderna and the University of Oxford in collaboration with the Serum Institute of India.

The trial is intended to establish whether the candidates can safely generate an immune response and protect against the Bundibugyo virus. Their effectiveness against the strain has not yet been established.

The development follows an earlier WHO recommendation, reported by PREMIUM TIMES in August, that Ervebo be prioritised for a clinical trial after preliminary animal studies suggested it might offer some cross-protection against Bundibugyo virus disease.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading

Health

Ebola: ₦100,000 weekly allowance for quarantined contacts was unplanned

info

Published

on

831280678 1536573021840993 5032481502414733176 n.jpg

The Nigeria Centre for Disease Control and Prevention (NCDC) has revealed that its decision to pay ₦100,000 weekly to people quarantined over possible exposure to Ebola was an unplanned, temporary measure introduced on compassionate grounds after some threatened to leave the facilities.

The NCDC Director-General, Jide Idris, disclosed this on Monday during an appearance on Channels Television’s Politics Today, explaining that the agency introduced the payments to address concerns raised by quarantined contacts who said their absence from home was affecting their families and businesses.

Mr Idris said the authorities had taken affected people out of their normal environments for public health reasons, making it necessary to consider their welfare while ensuring they complied with quarantine measures.

“Those people who were in the quarantine area, there are people who never planned to be there. We took them out of their comfort zones to put them there for public health reasons,” he said.

Mr Idris said the agency had taken responsibility for their feeding and accommodation but faced complaints from some quarantined contacts who said they had families to support and businesses to run.

He said some threatened to leave the facilities because of the disruption to their daily lives, a development he described as a potential public health concern.

PT WHATSAPP CHANNEL
Dangote Refinery AD

“If you allow them to leave the place, it’s a public health issue because you don’t know whether they will turn positive or who is ill,” he said.

Mr Idris explained that the financial support was introduced to ease tensions and encourage affected people to remain in quarantine for the period health authorities require.

He said the arrangement was temporary and had not been part of the agency’s original budget.

“It’s a temporary thing because it’s not something we’ve done,” he said, adding that the government had to intervene because the expected support from state governments was not forthcoming.

State governments’ responsibilities

Mr Idris said state governments were responsible for providing quarantine facilities and the resources needed to manage people placed under public health restrictions.

He said the NCDC stepped in to address the immediate welfare concerns of the quarantined contacts because the necessary support had not been provided.

The agency’s intervention, he explained, was intended to prevent people from leaving designated facilities before completing the required monitoring period.

Nigeria’s Ebola response

PREMIUM TIMES earlier reported that the NCDC approved a weekly allowance of N100,000 for each person quarantined following possible exposure to Nigeria’s confirmed Ebola patient in the Federal Capital Territory (FCT).

Speaking on Channels Television on Monday, Mr Idris said the number of identified contacts had increased to 54 after authorities traced an Uber driver who transported the patient to the first hospital where she sought treatment.

The contacts include healthcare workers, the patient’s husband, domestic staff and personnel involved in collecting samples.

They are being monitored for 21 days after their last possible exposure, in line with Ebola’s incubation period.

Nigeria confirmed the imported Ebola case on 20 October, its first since the 2014 outbreak. The patient, a 42-year-old Ugandan-born woman living in Abuja, was subsequently evacuated to Switzerland alongside her husband.

The woman is receiving treatment in Geneva, while her husband, who had shown no symptoms, remains in isolation in Zurich.

Following their evacuation, the World Health Organisation said Nigeria had no remaining confirmed Ebola cases, noting that contact monitoring and other public health measures continue.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading

Trending